L
7.77
0.44 (6.00%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Lexeo Therapeutics, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
1.4
| 分析师共识 | 5.0 |
| 内部交易活动 | -1.5 |
| 价格波动 | 1.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 1.40 |
|
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 0.49% |
| 机构持股比例 | 91.48% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 25.00 (Chardan Capital, 221.75%) | 购买 |
| 中 | 23.00 (196.01%) | |
| 低 | 19.00 (Leerink Partners, 144.53%) | 购买 |
| 平均值 | 22.33 (187.39%) | |
| 总计 | 3 购买 | |
| 平均价格@调整类型 | 7.69 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 14 Nov 2024 | 23.00 (196.01%) | 购买 | 7.78 |
| 31 Oct 2024 | 21.00 (170.27%) | 购买 | 7.90 | |
| Chardan Capital | 13 Nov 2024 | 25.00 (221.75%) | 购买 | 7.64 |
| 30 Oct 2024 | 23.00 (196.01%) | 购买 | 8.28 | |
| Leerink Partners | 13 Nov 2024 | 19.00 (144.53%) | 购买 | 7.64 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| TOWNSEND RICHARD NOLAN | - | 8.36 | -2,500 | -20,900 |
| 累积净数量 | -2,500 | |||
| 累积净值 ($) | -20,900 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 8.36 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| TOWNSEND RICHARD NOLAN | 职员 | 10 Dec 2024 | 自动卖出 (-) | 2,500 | 8.36 | 20,900 |
| TOWNSEND RICHARD NOLAN | 职员 | 10 Dec 2024 | 执行期权 | 2,500 | - | - |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合